Efficacy and Safety of Antiplatelet Therapy After Endovascular Aortic Repair
- Conditions
- Abdominal Aortic Aneurysms (AAA)Endovascular Aneurysm Repair (EVAR)
- Registration Number
- NCT06876727
- Lead Sponsor
- Samsung Medical Center
- Brief Summary
This study was a target trial emulation using the National Health Claims database established by the Korean National Health Insurance Service (K-NHIS). 8,325 patients were included.
- Detailed Description
Among these patients, any patients who were prescribed SAPT or DAPT at the date of discharge from the index hospitalization for standard EVAR were defined as being in the SAPT group (N=4,162) and the DAPT group (N=4,163), respectively.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 8325
- All patients who underwent EVAR for AAA and were successfully discharged
- Patients who had experienced a myocardial infarction
- Patients who had experienced a stroke
- Patients who had experienced percutaneous coronary intervention
- Patients who had history of peripheral disease
- Patients who had major bleeding event within 1 year of admission
- Those prescribed non-vitamin K antagonist oral anticoagulant or warfarin
- Patients who did not prescribe any antiplatelet therapy
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Major adverse cardiac and cerebrovascular events (MACCE) 1 year after EVAR composite of all-cause death, myocardial infarction (MI), or ischemic stroke
Major or clinically relevant non-major bleeding 1 year after EVAR Diagnostic codes in the primary or secondary position and transfusion receipt
Re-intervention or surgery for AAAs 1 year after EVAR Re-intervention or surgery for AAAs
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.